Management of imatinib-resistant patients with chronic myeloid leukemia

Pavan Kumar Bhamidipati; Hagop Kantarjian; Jorge Cortes; A. Megan Cornelison; Elias Jabbour

doi:10.1177/2040620712468289

Management of imatinib-resistant patients with chronic myeloid leukemia

Pavan Kumar Bhamidipati, Hagop Kantarjian, Jorge Cortes, A. Megan Cornelison, Elias Jabbour

Leukemia

Research output: Contribution to journal › Review article › peer-review

109 Scopus citations

Abstract

Since its approval in 2001 for frontline management of chronic myelogenous leukemia (CML), imatinib has proven to be very effective in achieving high remission rates and improving prognosis. However, up to 33% of patients will not achieve optimal response. This has led researchers to develop new second- and third-generation tyrosine kinase inhibitors. In this article, we review the mechanisms of resistance, recommendations for monitoring, assessment of milestones, and management options for patients with CML who are resistant to imatinib therapy. We further explain the potential pitfalls that can lead to unnecessary discontinuation, the prognosis of patients whose condition fails to respond to treatment, and the upcoming therapies.

Original language	English (US)
Pages (from-to)	103-117
Number of pages	15
Journal	Therapeutic Advances in Hematology
Volume	4
Issue number	2
DOIs	https://doi.org/10.1177/2040620712468289
State	Published - Apr 2013

Keywords

CML
imatinib resistance
treatment
tyrosine kinase inhibitor

ASJC Scopus subject areas

Hematology

Access to Document

10.1177/2040620712468289

Cite this

@article{b76979ceaac54279a0fef0b2ecddf7fc,

title = "Management of imatinib-resistant patients with chronic myeloid leukemia",

abstract = "Since its approval in 2001 for frontline management of chronic myelogenous leukemia (CML), imatinib has proven to be very effective in achieving high remission rates and improving prognosis. However, up to 33% of patients will not achieve optimal response. This has led researchers to develop new second- and third-generation tyrosine kinase inhibitors. In this article, we review the mechanisms of resistance, recommendations for monitoring, assessment of milestones, and management options for patients with CML who are resistant to imatinib therapy. We further explain the potential pitfalls that can lead to unnecessary discontinuation, the prognosis of patients whose condition fails to respond to treatment, and the upcoming therapies.",

keywords = "CML, imatinib resistance, treatment, tyrosine kinase inhibitor",

author = "Bhamidipati, {Pavan Kumar} and Hagop Kantarjian and Jorge Cortes and Cornelison, {A. Megan} and Elias Jabbour",

year = "2013",

month = apr,

doi = "10.1177/2040620712468289",

language = "English (US)",

volume = "4",

pages = "103--117",

journal = "Therapeutic Advances in Hematology",

issn = "2040-6207",

publisher = "Sage Publications",

number = "2",

}

TY - JOUR

T1 - Management of imatinib-resistant patients with chronic myeloid leukemia

AU - Bhamidipati, Pavan Kumar

AU - Kantarjian, Hagop

AU - Cortes, Jorge

AU - Cornelison, A. Megan

AU - Jabbour, Elias

PY - 2013/4

Y1 - 2013/4

N2 - Since its approval in 2001 for frontline management of chronic myelogenous leukemia (CML), imatinib has proven to be very effective in achieving high remission rates and improving prognosis. However, up to 33% of patients will not achieve optimal response. This has led researchers to develop new second- and third-generation tyrosine kinase inhibitors. In this article, we review the mechanisms of resistance, recommendations for monitoring, assessment of milestones, and management options for patients with CML who are resistant to imatinib therapy. We further explain the potential pitfalls that can lead to unnecessary discontinuation, the prognosis of patients whose condition fails to respond to treatment, and the upcoming therapies.

AB - Since its approval in 2001 for frontline management of chronic myelogenous leukemia (CML), imatinib has proven to be very effective in achieving high remission rates and improving prognosis. However, up to 33% of patients will not achieve optimal response. This has led researchers to develop new second- and third-generation tyrosine kinase inhibitors. In this article, we review the mechanisms of resistance, recommendations for monitoring, assessment of milestones, and management options for patients with CML who are resistant to imatinib therapy. We further explain the potential pitfalls that can lead to unnecessary discontinuation, the prognosis of patients whose condition fails to respond to treatment, and the upcoming therapies.

KW - CML

KW - imatinib resistance

KW - treatment

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84993699130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993699130&partnerID=8YFLogxK

U2 - 10.1177/2040620712468289

DO - 10.1177/2040620712468289

M3 - Review article

C2 - 23610618

AN - SCOPUS:84993699130

SN - 2040-6207

VL - 4

SP - 103

EP - 117

JO - Therapeutic Advances in Hematology

JF - Therapeutic Advances in Hematology

IS - 2

ER -

Management of imatinib-resistant patients with chronic myeloid leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this